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Background: MicroRNAs (miRNAs) play an important role in a tumor-suppressive or oncogenic manner in
carcinogenesis. Alteration expression patterns of miRNAs in gastric cancer (GC) are associated with cancer
initiation and progression. In the present study, we evaluated miR-29a-3p expression pattern and its function
in gastric carcinogenesis.
Methods: The expression of miR-29a-3p in GC tissue samples and cell lines was detected by quantitative real-time
PCR (qRT-PCR). After transfected with miR-29a-3p mimics or inhibitor, the cell proliferation, cell migration, and invasion
ability were assessed by CCK-8 assay, wound healing assay, and Trans-well assay, respectively. The level of CDK2, CDK4,
CDK6, and CyclinD1 were determined by qRT-PCR and Western blot.
Results: Compared with the corresponding non-tumor tissues, miR-29a-3p showed a significant down-regulated
expression in tumor tissues. In vitro functional assays demonstrated that enforced miR-29a-3p expression inhibited
cell proliferation by reducing the expression of CDK2, CDK4, and CDK6. Wound healing and Transwell assays revealed
that miR-29a-3p suppressed tumor metastasis in GC.
Conclusions: Our preliminary results suggest that altered expression of miR-29a-3p is involved in gastric cancer
process. The present study provides the first insight into the specific role of miR-29a-3p in gastric carcinogenesis.
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Gastric cancer (GC) is one of the malignant digestive
tract tumors which seriously threatens human health [1],
accounting for a major cause of cancer-related mortality
in China [2]. Although the tremendous improvements in
diagnosis and treatment technologies, the difficulty for
early diagnosis and the poor prognosis of advanced GC
still results in a low survival rate [3]. Multiple encoding or
non-coding gene expression alteration is involved in the
occurrence and progression of GC. MicroRNAs (miRNAs)
are small endogenous, non-coding, single-stranded RNAs* Correspondence: fanh@seu.edu.cn
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unless otherwise stated.[4], which inhibit the translation and stability of messen-
ger RNAs (mRNAs), controlling genes expression involved
in cellular processes such as cell-cycle regulation, differen-
tiation, apoptosis, and migration. Nowadays, it is shown
that miRNA closely relates to the process of tumor and
the development of tumor invasion and migration [5].
miRNA also acts as a biomarker stably expressed in serum
and provides new target for molecular target therapy of
various cancers [6]. Accumulating evidences have strongly
suggested that altered miRNA expression profiles and pat-
terns could play an important role in tumorigenesis as
oncogenes and tumor-suppressor genes [7]. Currently,
multiple abnormal expressions of miRNAs in gastric can-
cer have been observed, which are involved in gastric can-
cer cell proliferation, invasion, metastasis, and apoptosis,
as well as in radiotherapy and chemotherapy sensitivity
via regulating different tumor-related target genes [8-11].his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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could contribute to deeply understand the mechanisms of
GC development and identify diagnostic biomarkers and
therapeutic targets.
miR-29a-3p is a member of miR-29s family, which is
a conserved family of miRNA. Decreased expression of
miR-29s has been described in multiple cancers, includ-
ing GC [12,13]. Despite plenty of evidences showing that
miR-29s can function as a tumor-suppressor gene,
miR-29a-3p expression pattern in GCs still remains
partially unresolved. The present study revealed that
miR-29a-3p was significantly decreased in GC tissues
and was involved in cell growth, migration, and inva-
sion. These studies also provided novel insight into the
role of miR-29a-3p in gastric carcinogenesis which would
be crucial for the development of new strategies for GC
treatment.
Methods
Cell culture and oligonucleotides transfection
Human gastric adenoma cell lines, including GES-1,
SGC-7901, AGS, MCG803, and BGC-823, were obtained
from the Cell Bank of Chinese Academy of Science and
maintained in RPMI-1640 medium (Life Technologies,
Carlsbad, CA, USA) supplemented with 10% fetal bovine
serum (FBS, Invitrogen, Carlsbad, CA, USA), 100 U/ml
of penicillin and 100 mg/ml streptomycin (Invitrogen,
Carlsbad, CA) in a humidified incubator with 5% CO2
atmosphere at 37°C.
miR-29a-3p mimics/inhibitors and negative control
molecules (scramble control mimic and inhibitor) were
synthesized and purified by the GenePharma Company
(Shanghai, China). The sequences were shown in Additional
file 1: Table S1. They were transfected into cells at a final
concentration of 50 nM using Lipofectamine-2000 trans-
fection reagent (Invitrogen, Carlsbad, CA, USA) according
to the manufacturer’s protocol.
Tissue sample preparation
Fifty pairs of histopathologically confirmed GC tissues
and their adjacent non-cancerous tissue specimens were
collected between 2010 and 2013 from the Jiangning
Hospital of Nanjing, China. The study was approved by
the Committee for Ethical Review of Research at the
Jiangning Hospital of Nanjing in China, and the patients
signed informed consent forms. All tissue samples were
obtained from patients undergoing GC and immediately
snap frozen in liquid nitrogen until RNA and protein
extraction.
Real-time reverse transcriptase quantitative PCR
Total RNA was extracted from cell and tissue samples
with Trizol reagent (Invitrogen, Carlsbad, CA). For the de-
tection of miRNA expression, the primers used for stem-loop reverse transcription PCR (RT-PCR) and quantitative
PCR (qPCR) were synthesized and purified by RiboBio
(Guangzhou, China). The PCR conditions were 95°C for
30 s, followed by 40 cycles of 95°C for 30 s, 60°C for 30 s,
and 72°C for 30 s. The reactions were monitored using a
preheated real-time instrument (ABI step one, Life
Technologies). The relative expression ratio of miRNA
in gastric cancer tissues and cells was quantified by
the 2−ΔΔCT method. The primer sequences of gene ITGA6
and LAMA2 were shown in Additional file 2: Table S2.
Western blot
Western blots were performed using Mouse anti-CDK2,
anti-CDK4, anti-CDK6, and anti-cyclin D1 were pur-
chased as part of the Cell Cycle Regulation Sampler Kit
(Cell Signaling Technology, Danvers, MS, USA). Mouse
anti-β-actin was purchased from Sigma-Aldrich (St. Louis,
MO, USA). Protein detection was performed with Super
Signal chemiluminescence substrate (Pierce, Rockford, IL,
USA).
Cell proliferation assay
The miRNA mimics/inhibitor was synthesized and puri-
fied by GenePharma Company (Shanghai, China) and
transfected into the cells at a final concentration of 50
nM/100 nM using Lipofectamine-2000 transfection re-
agent (Invitrogen). One day before transfection, 5.0 × 103
BGC-823 cells and MCG803 in a 100-μl growth medium
were plated in each well of a 96-well plate. The cells were
then transfected with 50 nM of various synthetic miRNA
mimics and corresponding control, and 100-nM inhibi-
tor and corresponding control, using Lipofectamine-2000
(Invitrogen) according to the manufacturer’s instruction.
A cell counting kit-8 (CCK-8) (Dojindo Laboratories,
Kumamoto, Japan) was used to measure the cellular
growth following the manufacturer’s instruction. Cell
proliferation was assessed at different time points (0,
24, 48, and 72 h). Triplicate independent experiments
were performed.
Migration and invasion assay
Cell mobility was subjected to the wound healing assay
analysis as described previously [14]. A scratch wound was
generated using a 200-μl pipette tip on confluent cell
monolayers in a six-well plate. Cells were then washed with
a fresh medium to remove floating cells, and the spread of
the wound closure was observed after 48 h and photo-
graphed under a microscope (Olympus, Tokyo, Japan).
The potential for migration and invasion of trans-
fected cells were evaluated by a Transwell assay (Life
Technologies). Cells were grown to 70% confluence and
transfected for 24 h with miR-29a-3p mimics or control
mimics and miR-29a-3p inhibitor or control inhibitor, re-
spectively. In the migration assay, cells were cultured in a
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non-coated Transwell insert. In the lower chamber, a 600-
ml medium with 10% FBS was used as a chemo-attractant
to encourage cell migration. In the invasion assay, the
upper chamber of the Transwell inserts were coated with
50 ml of 1.0 mg/ml Matrigel (Millipore, Billerica, MA,
USA), and cells were plated in the upper chamber of the
Matrigel-coated Transwell insert (Millipore, Billerica, MA,
USA). After incubated for 24 h, the non-migrating or
non-invading cells were gently removed with a cotton
swab. All cells were stained using 0.1% crystal violet stain-
ing and counted in five fields under an inverted micro-
scope. The independent experiments were repeated three
times.
Statistical analysis
The independent Student’s t-test was used to compare
the results expressed as mean ± SD between any two
pre-selected groups. A P value less than 0.05 was consid-
ered statistically significant. To determine correlations
between variables, Pearson’s correlation coefficient was
calculated.
Results
miR-29a-3p was decreased in GC tissue samples and cell
lines
To validate the expression of miR-29a-3p in GC tissue
samples and cell lines, we conducted quantitative real-
time PCR (qRT-PCR) in 50 GC tissues and the corre-
sponding normal tissues and 4 GC cell lines and 1 gastric
epithelial cell line (real-time quantitative PCR method inFigure 1 Decreased expression of miR-29a-3p in GC specimens and c
tissues (n = 50). The value (defined as “fold difference”) indicated the ratio o
the matched non-tumor tissues. Twenty- one out of fifty GC cases showed
the number of detected GC cases. (B) Scatter plots of miR-29a-3p fold chan
the lines indicated the mean ± SD. The level of miR-29a-3p mRNA was sig
counterparts (P = 0.012, Paired Student’s t-test). (C) Semi-quantification
Data were presented as means ± SD from at least three separate experAdditional file 3). Compared to the paired non-tumor
tissues, 42% (21/50) of GC cases showed decreased
expression of miR-29a-3p (defined as greater than a
two-fold decrease) (Figure 1A). The average fold change
of miR-29a-3p was significantly lower in tumor tissues
than that in non-tumor tissues (P = 0.012, Paired student’s
t-test; Figure 1B). Decreased miR-29a-3p was correlated
with the degree of cell differentiation (Table 1). Four GC
cell lines (SGC-7901, AGS, MCG803, and BGC-823)
showed lower level expression of miR-29a-3p compared
with the GES-1, normal gastric mucosa cells (Figure 1C).
These data indicated that reduced expression of miR-29a-3p
might play an important role in gastric carcinogenesis.
miR-29a-3p has cell proliferation suppression effects
in vitro
miR-29a-3p expression level was correlated with the de-
gree of differentiation which partly depended on cell pro-
liferation. Therefore, we assessed the role of miR-29a-3p
by gain- and loss-function experiments on cell prolifera-
tion in GC cell lines. BGC-823 and MCG803 cells, which
showed moderate miR-29a-3p mRNA, were used to ex-
plore the cell proliferation suppression role of miR-29a-3p
(Figure 2A,B). BGC-823 and MCG803 cells were trans-
fected with a mimic or inhibitor and their corresponding
scramble sequence control, respectively. The cell prolifer-
ation suppression effects of miR-29a-3p were evaluated by
CCK-8 assay. Cell growth curve assay revealed that cells
transfected with miR-29a-3p inhibitor grew more rapidly
than the control group, while miR-29a-3p mimics inhib-
ited the cell growth compared to the control. In order toell lines. (A) qRT-PCR analysis showing miR-29a-3p mRNA level in GC
f the miR-29a-3p mRNA expression level (fold change) in GC tissues to
a decreased expression of miR-29a-3p (T < N). The bar chart showed
ge in GC tissues and their matched non-tumor tissues. In both panels,
nificantly lower in GC tumor tissues compared to the non-tumor
of miR-29a-3p expression (fold change) in GC cell lines by qRT-PCR.
iments.
Table 1 Correlation of the expression of miR-29a-3p with
clinicopathologic feature











Tunica mucosa 4 2
Mucous layer outside 13 17
Note: clinicopathologic features of 7 GC tissue samples are not included due
to imperfection, so only 43 GC tissue samples were analyzed. *Significant
differences are shown.
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further examined the expression of several cell-cycle
regulatory proteins in transfected miR-29a-3p mimic
or inhibitor cells. The results showed that the expres-
sion level of CyclinD1, CDK2, CDK4, and CDK6 were
negatively related to the expression level of miR-29a-3p
(Figure 2C). These results implied that miR-29a-3p might
contribute to the stimulation of cell-cycle progression by
enhancing the G1/S transition.
miR-29a-3p suppressed GC cell migration and invasion
To investigate the role of miR-29a-3p in GC migration
and invasion, miR-29a-3p mimics/inhibitor and their
corresponding scramble sequences were transfected into
BGC-823 cells. Transwell assay and wound healing method
were performed in vitro. The efficiency of the transfection
was tested by measuring the mature miRNA levels by
qRT-PCR (data not shown). After transiently transfecting
miR-29a-3p mimics or a negative control into BGC-823
cells, the wound healing assay showed that the forced
expression of miR-29a-3p displayed a notable slower re-
covery compared with control cells (Figure 3A). Similarly,
the Transwell migration assay showed that the over-
expression of miR-29a-3p was associated with significantly
less migration than the control (P < 0.05, Figure 3B, left).
The over-expression of miR-29a-3p cells also revealed a
significant reduction in invasive ability in a Matrigel inva-
sion assay (P < 0.05, Figure 3C, left). These results sug-
gested that miR-29a-3p was important not only for GC
cell invasion but also for cell migration. To further con-
firm the suppressive effects of miR-29a-3p on GC cell mi-
gration and invasion, BGC-823 was transiently transfected
with miR-29a-3p inhibitors or a negative control. Thedeletion of miR-29a-3p significantly increased the migra-
tory and invasive capabilities of the GC cells, as assessed
by wound healing (Figure 3B, right) and a Transwell
assay (P < 0.05, Figure 3C, right). Collectively, these re-
sults indicated that miR-29a-3p effectively abolished GC
cell migration and invasion, which therefore might con-
tribute to the early stages of the malignant progression of
GC.
Discussion
miRNA is an important regulator of gene expression at
the post-transcriptional level and participates in cell de-
velopment, differentiation, proliferation, cell-cycle con-
trol, apoptosis, and metabolism [4]. Increased evidences
have implied that miRNAs function as oncogene and
tumor-suppressor genes, regulating the expression and
function of their related target genes during the biological
process of cancer cells. Our previous study showed that
there was distinct miRNA profiling between GC tissues
and matched non-tumor tissues based on the miRNA
microarray analysis (Additional file 4: Table S4). In the
present study, miR-29a-3p was selected as a candidate
miRNA due to its down-regulation in tumor tissues. miR-
29a-3p is one of the members of miR-29 family, which also
includes miR-29b and miR-29c. Accumulating evidences
have shown that the aberrant expression of miR-29s are
prevalent in multiple cancer types and are involved in
complex regulatory process by targeting multiple factors
associated with several common pathways, indicating its
critical role in carcinogenesis and cancer progression
[14-18]. miR-29a has two different transcripts, which are
miR-29a-3p and miR-29a-5p, respectively. Neither of them
has been reported specific aberrant expression in tumors.
Recent studies have found that miR-29a is up-regulated
in indolent human B cell chronic lymphocytic leukemia
(B-CLL) and acute myeloid leukemia (AML) [19,20]. How-
ever, some researches reveal that miR-29a is down-regulated
in neuroblastoma, sarcomas, and brain tumors [12,21]. In
fact, miR-29a could suppress cell proliferation and induce
cell-cycle arrest via the down-regulation of p42.3 expres-
sion [22]. These inconsistent findings indicate that dysreg-
ulation of miR-29a in various cancers may be dependent
on the cellular microenvironment, especially with regard
to detecting different transcripts of miR-29a-3p. In
the present study, we analyzed the expression levels of
miR-29a-3p transcript in GC tissue samples and GC cells
and its primary biological function on GC cells. We found
that decreased expression of miR-29a-3p in GC tumor
tissues was related to the degree of cell differentiation.
Decreased miR-29a-3p expression promoted gastric can-
cer cell proliferation via reducing the expression of cell-
cycle regulators including: CDK2, CDK4, and CDK6. In a
way, our finding might be consistent with the reporting of
Cui Y et al. [22].
Figure 2 CCK-8 assay was performed to analyze the effect of miR-29a-3p on cell proliferation ability in GC cells. (A) The cell growth
rates of BGC-miR-29a-3p-mimics (upper) and MCG-miR-29a-3p-mimics (bottom) were detected by the CCK-8 assay. miR-29a-3p significantly
decreased cell growth rates (*P < 0.05; independent student’s t-test). (B) The cell growth rates of BGC-miR-29a-3p-inhibitor (upper) and
MCG-miR-29a-inhibitor (bottom) were detected by the CCK assay. miR-29a-3p knockdown significantly increased cell growth rates (*P < 0.05;
independent student’s t-test). (C) Expression of CDK2, CDK4, CDK6, and CyclinD1 were detected in BGC-823 or MCG-803 transfected with miR-29a-3p
mimics (left)/inhibitor (right). β-actin was used as a loading control. OD, optical density.
Zhao et al. World Journal of Surgical Oncology  (2015) 13:101 Page 5 of 7Many miRNAs have been identified as key players in
metastasis and invasion process of tumor. In prostate can-
cer, miR-29a is considered as a putative tumor-suppressive
miRNA, contributing to cell migration and invasion
[23]. miR-29 family plays a dominant role in regulatingextracellular matrix genes, such as collagens, LAMA2,
integrin β, Mmp2, fibrillin, secreted protein, acidic, and
Sparc [16,24], consequently contributing to the promotion
of cancer cell migration and metastasis. The present find-
ings showed that miR-29a-3p significantly inhibits the
Figure 3 The effect of miR-29a-3p on GC cell migration and invasion. (A) Wound healing assays on the confluent layers of miR-29a-3p
mimics-transfected BGC-823 cells (left) and miR-29a-3p inhibitor-transfected BCG-823 cells (right). Representative images of wound healing assays
were acquired at 0 and 48 h after wounding. Representative images (upper) and bar graphs (bottom) depicting the migration (B) and invasion
(C) ability of BGC-823 cell after the 48 h transfection of negative control mimics or miR-29a-3p mimics (left) (*P < 0.05) and miR-29a-3p inhibitor
(right) compared to its control (*P < 0.05).
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help of bioinformatics prediction (Target scan, miRanda,
miRWalk, and miRDB), ITGA6, LAMA2, and DNMT3A
were identified as direct targets of miR-29a-3p. Thus,
the function of miR-29a-3p in metastasis depends on
its target regulation. Although we evaluated its poten-
tial target gene ITGA6, LAMA2 expression in miR-29a-
3p mimic, and inhibitor-transfected cells (Additional
file 5: Figure S5), future studies should be required to
validate the association between miR-29a-3p and tar-
gets. These results indicate that miR-29a-3p may serveas a potential predictor for prognosis of gastric cancer
patients.
Conclusions
In conclusion, the present study reveals that miR-29a-3p is
down-regulated in GC, and it may contribute to the occur-
rence of gastric cancer via influencing cell proliferation,
migration, and invasion. These findings provide evidence
for the clinical value of miR-29a-3p as targets for GC ther-
apy, although the precise regulatory mechanism and spe-
cific targets should be explored in the future study.
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Additional file 1: Table S1. miR-29a-3p mimics/inhibitor and control
sequences. miR-29a-3p mimic and its control sequences were used to
enforce the expression of miR-29a-3p in gastric cancer cells. miR-29a-3p
inhibitor and its control sequences were used to knock down the
expression of miR-29a-3p in gastric cancer cells.
Additional file 2: Table S2. Primers sequences for qPCR analysis. These
primers were used to analyze expression of potential target genes of
miR-29a-3p.
Additional file 3: Real-time reverse transcriptase quantitative
PCR for detecting miRNA expression. For the detection of miRNA
expression, the primers used for stem-loop RT-PCR and qPCR were
synthesized and purified by RiboBio. The methods for analyzing the
expression level of miRNA.
Additional file 4: Table S4. Down-regulated ≥3-fold microRNA
profiling in gastric cancer cases. Information showed in this table
was down-regulated miRNA in gastric cancer tissues compared with
matched from microRNA array analysis.
Additional file 5: Figure S5. The target gene ITGA6, LAMA2, and
DNMT3A expression in miR-29a-3p mimic and inhibitor-transfected cells
analyzed by qPCR. With the help of bioinformatics prediction (Target
scan, miRanda, miRWalk, and miRDB), ITGA6, LAMA2, and DNMT3A were
identified as direct targets of miR-29a-3p. qPCR analysis showed that the
ITGA6, LAMA2, and DNMT3A mRNA level were inhibited after transfected
with miRNA-29a-3p mimic, and after being transfected with miR-29a-3p
inhibitor, the ITGA6, LAMA2, and DNMT3A mRNA levels were increased.
Abbreviations
GC: gastric cancer; qRT-PCR: quantitative reverse-transcription polymerase
chain reaction.
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